<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 1. Pharmacokinetic Values for Plasma Hydrodolasetron Following Oral Administration of ANZEMET<footnote>: mean values</footnote>
</caption>
<col align="left" valign="top" width="32%"></col>
<col align="center" valign="top" width="11%"></col>
<col align="center" valign="top" width="13%"></col>
<col align="center" valign="top" width="16%"></col>
<col align="center" valign="top" width="14%"></col>
<col align="center" valign="top" width="14%"></col>
<thead>
<tr>
<th stylecode="Botrule Lrule"></th>
<th stylecode="Botrule Lrule">Age<br/>(years)</th>
<th stylecode="Botrule Lrule" valign="bottom">Dose</th>
<th stylecode="Botrule Lrule">CL<sub>app</sub>
<br/>(mL/min/kg)</th>
<th stylecode="Botrule Lrule">t<sub>1/2</sub>
<br/>(h)</th>
<th stylecode="Botrule Lrule Rrule">C<sub>max</sub>
<br/>(ng/mL)</th>
</tr>
</thead>
<tfoot>
<tr>
<td align="left" colspan="6">CL<sub>app</sub>: apparent clearance    t<sub>1/2</sub>:  terminal elimination half-life     ( ): coefficient of variation in %</td>
</tr>
</tfoot>
<tbody>
<tr>
<td stylecode="Botrule Lrule">Young Healthy Volunteers (N=30)</td>
<td stylecode="Botrule Lrule">19–45</td>
<td stylecode="Botrule Lrule">200 mg</td>
<td stylecode="Botrule Lrule">13.4 (29%)</td>
<td stylecode="Botrule Lrule">8.1 (18%)</td>
<td stylecode="Botrule Lrule Rrule">556 (28%)</td>
</tr>
<tr>
<td stylecode="Botrule Lrule">Elderly Healthy Volunteers (N=15)</td>
<td stylecode="Botrule Lrule">65–75</td>
<td stylecode="Botrule Lrule">2.4 mg/kg</td>
<td stylecode="Botrule Lrule">9.5 (36%)</td>
<td stylecode="Botrule Lrule">7.2 (32%)</td>
<td stylecode="Botrule Lrule Rrule">662 (28%)</td>
</tr>
<tr>
<td stylecode="Lrule">Cancer Patients</td>
<td stylecode="Lrule"></td>
<td stylecode="Lrule"></td>
<td stylecode="Lrule"></td>
<td stylecode="Lrule"></td>
<td stylecode="Lrule Rrule"></td>
</tr>
<tr>
<td stylecode="Lrule">  Adults (N=61)<footnote>: analyzed by nonlinear mixed effect modeling with data pooled across dose strengths</footnote>
</td>
<td stylecode="Lrule">24–84</td>
<td stylecode="Lrule">25–200 mg</td>
<td stylecode="Lrule">12.9 (49%)</td>
<td stylecode="Lrule">7.9 (43%)</td>
<td stylecode="Lrule Rrule">
<sub>--</sub>
<footnote>: sampling times did not allow calculation</footnote>
</td>
</tr>
<tr>
<td stylecode="Lrule">  Adolescents (N=13)</td>
<td stylecode="Lrule">12–17</td>
<td stylecode="Lrule">0.6–1.8 mg/kg</td>
<td stylecode="Lrule">26.5 (67%)</td>
<td stylecode="Lrule">6.4 (30%)</td>
<td stylecode="Lrule Rrule">374<footnote>: results from adolescents (dose=1.8 mg/kg, N=3) the maximum dose exceeded 100 mg. When data from patients who received greater than 47 mg (N=9) are combined and normalized to the 1.8 mg/kg dose with a cap of 100 mg, the mean C<sub>max</sub> was 229 ng/mL (51%).</footnote> (32%)</td>
</tr>
<tr>
<td stylecode="Botrule Lrule">  Children (N=19)</td>
<td stylecode="Botrule Lrule">3–11</td>
<td stylecode="Botrule Lrule">0.6–1.8 mg/kg</td>
<td stylecode="Botrule Lrule">44.2 (49%)</td>
<td stylecode="Botrule Lrule">5.5 (39%)</td>
<td stylecode="Botrule Lrule Rrule">217<footnote>: results from children (dose=1.8 mg/kg, N=7)</footnote> (67%)</td>
</tr>
<tr>
<td stylecode="Botrule Lrule">Patients with Severe Renal Impairment (N=12)<br/>(Creatinine clearance ≤10 mL/min)</td>
<td stylecode="Botrule Lrule">28–74</td>
<td stylecode="Botrule Lrule">200 mg</td>
<td stylecode="Botrule Lrule">7.2 (48%)</td>
<td stylecode="Botrule Lrule">10.7 (29%)</td>
<td stylecode="Botrule Lrule Rrule">701 (21%)</td>
</tr>
<tr>
<td stylecode="Botrule Lrule">Patients with Severe Hepatic Impairment (N=3)</td>
<td stylecode="Botrule Lrule">42–52</td>
<td stylecode="Botrule Lrule">150 mg</td>
<td stylecode="Botrule Lrule">8.8 (57%)</td>
<td stylecode="Botrule Lrule">11.0 (36%)</td>
<td stylecode="Botrule Lrule Rrule">410 (12%)</td>
</tr>
</tbody>
</table>